<DOC>
	<DOC>NCT01470937</DOC>
	<brief_summary>This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.</brief_summary>
	<brief_title>Early Diabetes Intervention Program</brief_title>
	<detailed_description>A double blind, randomized, placebo-controlled clinical trial of acarbose in subjects with type 2 diabetes (an FDA-approved indication). Subjects were identified who had diabetes by glucose tolerance test criteria but non-diabetic fasting glucose concentrations. Treatment interventions were assessed for their ability to delay worsening of fasting glucose control.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Fasting plasma glucose &lt;140 mg/dL 75 g OGTT 2hr glucose &gt;120 mg/dL BMI &gt; 25 OR history of gestational diabetes mellitus OR family history of type 2 diabetes Age at least 25 years Cancer within 5 years Chronic infectious disease (HIV, Hepatitis) CVD event within 6 months Uncontrolled hypertension or requiring beta blockers or thiazide diuretics for control elevated AST or ALT Serum creatinine &gt;1.4 mg/dL (men) or &gt;1.3 mg/dL (women) TG &gt;600 mg/dL Known glucosidase intolerance Inability to comply with protocol requirements.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>diabetes acarbose alphaglucosidase prevention</keyword>
</DOC>